Medical Therapies buys midkine IP
Thursday, 03 July, 2008
Sydney pharma Medical Therapies [ASX: MTY] has completed the purchase of the IP surrounding midkine protein-related technology assets from Japanese company Cell Signals Inc after receiving shareholder approval.
Cell Signals today traded all midkine protein-related IP rights to Medical Therapies, in exchange for 20 million shares of Medical Therapies stock.
These include patents, trademarks, manufacturing information and technical know-how, on top of all Cell Signals' stocks of midkine protein and reagents.
The agreement was announced in April. Midkine is a neurite growth promoting factor, active in oncogenesis and inflammation.
Hormone therapy shifts body proteins to match gender identity
Researchers have discovered that gender-affirming hormone therapy can alter body proteins to...
Targeting 'molecular bodyguards' weakens prostate cancer cells
Research reveals that two enzymes — PDIA1 and PDIA5 — act as 'molecular...
Females found to carry a higher genetic risk of depression
An international team of scientists has discovered about twice as many genetic 'flags'...
